P-251: Comparative effectiveness of teclistamab versus real-world physician’s choice of therapy for patients with triple-class exposed relapsed/refractory multiple myeloma

Amrita Krishnan; Ajay Nooka; Ajai Chari; Alfred Garfall; Thomas Martin; Sandhya Nair; Xiwu Lin; Keqin Qi; Anil Londhe; Lixia Pei; Eric Ammann; Rachel Kobos; Jennifer Smit; Trilok Parekh; Alexander Marshall; Mary Slavcev; Saad Usmani

doi:10.1016/S2152-2650(22)00581-X

$P-251: Comparative effectiveness of teclistamab versus real-world physician’s choice of therapy for patients with triple-class exposed relapsed/refractory multiple myeloma$

Abstract

Peer reviewed

P-251: Comparative effectiveness of teclistamab versus real-world physician’s choice of therapy for patients with triple-class exposed relapsed/refractory multiple myeloma

Amrita Krishnan, Ajay Nooka, Ajai Chari, Alfred Garfall, Thomas Martin, Sandhya Nair, Xiwu Lin, Keqin Qi, Anil Londhe, Lixia Pei, …

Clinical lymphoma, myeloma and leukemia, Vol.22, p.S174

08/2022

DOI: 10.1016/S2152-2650(22)00581-X

View Online

Details

Title: Subtitle: P-251: Comparative effectiveness of teclistamab versus real-world physician’s choice of therapy for patients with triple-class exposed relapsed/refractory multiple myeloma
Creators: Amrita Krishnan
Ajay Nooka
Ajai Chari
Alfred Garfall
Thomas Martin
Sandhya Nair
Xiwu Lin
Keqin Qi
Anil Londhe
Lixia Pei
Eric Ammann
Rachel Kobos
Jennifer Smit
Trilok Parekh
Alexander Marshall
Mary Slavcev
Saad Usmani
Resource Type: Abstract
Publication Details: Clinical lymphoma, myeloma and leukemia, Vol.22, p.S174
DOI: 10.1016/S2152-2650(22)00581-X
ISSN: 2152-2650
eISSN: 2152-2669
Language: English
Date published: 08/2022
Academic Unit: Epidemiology
Record Identifier: 9984364362102771

Metrics

26 Record Views